Beyond cardiovascular data, retatrutide is also being studied in adults living with type 2 diabetes (TRIUMPH-2) and in metabolic dysfunction-associated steatohepatitis (MASH), a form of advanced fatty liver disease
As mentioned earlier, Wegovy has been FDA-approved, indicating that it has undergone clinical trials to assess its effectiveness, safety, and other relevant factors
Reports of heart valve disease associated with fenfluramine, texfenfluramine, and phentermine raised concerns about drug treatment of obesity since 2000 [10,11]
However, these mechanisms may also cause significant muscle loss, gastrointestinal issues, and there is potential for malnutrition and loss of lean body mass in some individuals
Approximately 11.9-fold increase in endogenous MOTS-c levels have been found in skeletal muscle following exercise (compared to pre-exercise values), and this increase can remain for 4 hours following exercise (19)
"Up to two thirds of patients may encounter some side effects